LEADERSHIP INSIGHTS

Criticaleye's Leadership Insight newsletter is read bi-weekly by leaders across our Community.



Choose your timeframe and then click on any of the topics below to see the corresponding newsletter. If you would like to comment further on any of these topics, write to us via info@criticaleye.com.




Building Faster and Fitter Operating Models

In recent years, many CEOs and senior executives have come to realise that their organisations are too traditional, heavily matrixed and increasingly disconnected with their customers. The end result in these instances is clunky businesses with swelling overheads and a lack of accountability across management. [read more]

Riding the Growth Wave in Asia

Economic momentum may have slowed down, but Asia continues to be the dominant force in driving global growth. The difficulty for leaders is to position their businesses in ways that overcome the current inflationary – or, in China’s case, deflationary – cost pressures at play to emerge strongly when the recovery begins. [read more]

The Mindset of the CHRO

Gone are the days of the CHRO as simply the keeper of personnel files and payroll. Today's CHRO is a strategic powerhouse, a trusted advisor to the C-suite and a champion for the entire organisation. This transformation reflects the evolving needs of businesses in a competitive and ever-changing landscape. [read more]

Growth in a High-octane Landscape

By now, the disruptive forces at play in the current environment are well documented. High interest rates, geopolitical volatility and rapid technological advancement are just three examples of areas occupying the minds of growth company leaders when it comes to decisions around strategy, growth and investment. [read more]











Veolia Water Technologies Concentrix Mayborn Group NATS London Stock Exchange E.ON UK Amazon UK Accenture Lightsource bp AlixPartners Robert Walters LDC Google Tullow Oil plc Bunzl plc Redwood Bank Drax Group plc Eightfold AI Salesforce Workday Eton Bridge Partners Legal & General Investment Management GlaxoSmithKline plc Royal London Group